Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
Gastrointestinal Endoscopy and Medicine, Hiroshima University Hospital, 1-2-3, Kasumi, Minamiku, Hiroshima, 734-8551, Japan.
Esophagus. 2023 Jul;20(3):541-547. doi: 10.1007/s10388-023-00999-w. Epub 2023 Apr 7.
Definitive chemoradiotherapy (DCRT) is a curative treatment option for cT1bN0M0 esophageal squamous cell carcinoma (ESCC); however, local residual disease and recurrence after complete remission may occur. We aimed to identify endoscopic findings associated with the risk of non-radical cure (local remnant or recurrence) after DCRT for cT1bN0M0 ESCC.
We retrospectively analyzed 40 consecutive patients with cT1bN0M0 ESCC who had undergone DCRT between January 2007 and December 2017. We examined the endoscopic findings in patients with residual or recurrent (RR) disease (RR group) and those without RR disease [non-RR (NRR) group] after DCRT. We also evaluated outcomes after DCRT for each endoscopic finding.
There were 10 patients in the RR group and 30 patients in the NRR group. The RR group had a significantly larger tumor size and a higher proportion of lesions with type 0-I. The 5-year relapse-free survival rate was significantly lower in type 0-I and in the presence of B3 vessels. Endoscopic findings in 15 patients with cT1bN0M0 ESCC, type 0-I, who underwent DCRT revealed significantly more reddish lesions in the RR group compared to the NRR group.
cT1bN0M0 ESCC large size, with B3 vessels, and type 0-I has a high risk of non-radical cure after DCRT, especially the reddish type 0-I, which may need to be considered for treatment similar to advanced cancer, including surgery with preoperative DCRT.
根治性放化疗(DCRT)是 cT1bN0M0 食管鳞癌(ESCC)的一种有治愈可能的治疗选择;然而,在完全缓解后仍可能存在局部残留病变和复发。我们旨在确定与 DCRT 后 cT1bN0M0 ESCC 非根治性治愈(局部残留或复发)相关的内镜发现。
我们回顾性分析了 2007 年 1 月至 2017 年 12 月期间接受 DCRT 的 40 例连续 cT1bN0M0 ESCC 患者。我们检查了 DCRT 后存在残留或复发(RR)疾病(RR 组)和无 RR 疾病[非 RR(NRR)组]患者的内镜发现。我们还评估了每种内镜发现的 DCRT 后结局。
RR 组有 10 例患者,NRR 组有 30 例患者。RR 组肿瘤尺寸明显较大,0-I 型病变比例较高。0-I 型和存在 B3 血管的患者 5 年无复发生存率明显较低。15 例接受 DCRT 的 cT1bN0M0 ESCC 患者,0-I 型,RR 组内镜下红色病变明显多于 NRR 组。
cT1bN0M0 ESCC 大尺寸,存在 B3 血管,0-I 型,DCRT 后非根治性治愈风险高,尤其是红色 0-I 型,可能需要考虑类似晚期癌症的治疗,包括术前 DCRT 的手术。